Kathleen A. Arntsen is the President & CEO of Lupus and Allied Diseases Association and has been a passionate and diplomatic leader, patient advocate and warrior for the lupus, rheumatology and autoimmune communities for the past thirty-three years. In addition to leading LADA, Kathleen coordinates the Lupus Agencies of NYS and is the Patient Representative for the Autoantibody Standardization Committee in Rheumatic and Related Disorders, and a member of the Advancing Lupus Pillars for Health Advancement (ALPHA) Project Global Advisory Committee.
Known as a resilient activist who quickly coalesces others to support advocacy and research initiatives, Kathleen has provided public testimony before the FDA, Congress, and various federal and state agencies. She is strongly committed to ensuring all Americans have access to the most appropriate and affordable medical care and treatments and is an active member of numerous national and state coalitions. Kathleen has been unwavering in her support of innovative lupus research initiatives and patient empowerment programs aimed at enhancing quality of life.
Kathleen has fought tenaciously to ensure that the patient voice is included and recognized as an equal stakeholder in the healthcare, regulatory and public policy arenas and across the research continuum. She served as the only Lupus Patient Representative at the FDA for eight years and was a driving force behind the Lupus Patient Focused Drug Development (PFDD) Initiative, co-leading the effort with the Lupus Foundation of America and the Lupus Research Alliance. Kathleen’s background in insurance marketing, sales training, and medical billing, combined with her patient and provider community interactions and personal health journey, have helped to shape her into one of the most powerful and unique advocates in the nation. Kathleen has received numerous awards for her efforts and is a graduate of Colgate University.